Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101690 | 0.77 | — | — | |
| SCHEMBL24414580 | 0.68 | KRAS (0.42) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL30991780 | 0.68 | KRAS (0.42) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL24414579 | 0.67 | CDC7 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL30991791 | 0.67 | CDC7 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL21608546 | 0.61 | CYP2C9 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL21608419 | 0.61 | CYP2C9 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL21555215 | 0.60 | CYP2C9 (0.44) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL743854 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL1186779 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028940-A1 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028940-A1 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | CYP2C9 1720/4885TSHR 285/4885CYP2C19 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.